Drug Trial Radar · NCT02577926
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
207
Actual
Start
Oct 2015
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- RWTH Aachen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Novartis Pharmaceuticals
- First posted
- Oct 16, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) comprise a group of clonal hematological malignancies that are characterized by chronic myeloproliferation, splenomegaly, different degrees of bone marrow fibrosis, and disease-related symptoms including pruritus, night sweats, fever, weight loss, cachexia, and diarrhea. In addition, due to elevated numbers of leucocytes, erythrocytes and/or platelets, the disease course can be complicated by thromboembolic disease, hemorrhage, and leukemic transformation as well as myelofibrosis. Patients with polycythemia vera (PV) typically harbor an increased number of blood cells from all three hematopoietic cell lineages due to clonal amplification of hematopoetic stem cells, while patients with essential thrombocythemia (ET) typically show a predominant expansion of the megakaryocytic lineage. Most patients with PV below the age of 60 years are currently being treated with acetylsalicylic acid +/- phlebotomy only, and patients with low-risk ET have an almost normal life expectancy and often do not require specific treatment. However, PV- as well as ET-patients with a higher risk for complications require cytoreductive treatment. In addition, constitutional symptoms can be unbearable to patients even in the absence of bona fide high risk factors, and these patients may similarly benefit from antineoplastic therapy.
Conditions
- Polycythemia Vera (PV)
- Essential Thrombocythemia (ET)
Interventions
RuxolitinibDrug
Ruxolitinib is a JAK1/2-specific tyrosine kinase inhibitor (TKI) which has been approved for the treatment of symptomatic myelofibrosis. The compound was shown to be superior to hydroxyurea in reducing splenomegaly and constitutional symptoms.
BATDrug
BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc).
Primary outcomes
What the sponsor says the trial is designed to measure.
- The rate of complete clinicohematologic response rate (CHR) as defined by Barosi et al 2009Time frame: at month 6
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Charite Universitätsmedizin Berlin; Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie
Berlin, Germany
Universitätsklinikum Freiburg - Klinik für Innere Medizin I
Freiburg im Breisgau, Germany
Universitätsklinik Jena - Klinik für Innere Medizin II
Jena, Germany
UNIVERSITÄTSKLINIKUM Schleswig-Holstein - Klinik für Hämatologie und Onkologie, Campus Lübeck
Lübeck, Germany
Universitätsmedizin Mannheim III. Medizinische Klinik Hämatologie und Internistische Onkologie
Mannheim, Baden-Wurttemberg, Germany
Universitätsklinikum Ulm Klinik für Innere Medizin III
Ulm, Baden-Wurttemberg, Germany
Rems-Murr Klinikum Winnenden
Winnenden, Baden-Wurttemberg, Germany
Studienzentrum Aschaffenburg
Aschaffenburg, Bavaria, Germany
III. Medizinischen Klinik des Klinikums rechts der Isar der TU München
Müchen, Bavaria, Germany
Klinikum Nürnberg Nord Medizinische Klinik 5
Nuremberg, Bavaria, Germany
Universitätsklinikum Hamburg Eppendorf Klinik und Poliklinik für Onkologie, Hämatologie und KMT mit Sektion Pneumologie
Hamburg, Free and Hanseatic City of Hamburg, Germany
Universitätsmedizin Mainz III. Medizinische Klinik und Poliklinik
Mainz, Hesse, Germany
Uniklinik RWTH Aachen
Aachen, North Rhine-Westphalia, Germany
Universitätsklinikum Bonn Medizinische Klinik und Poliklinik III
Bonn, North Rhine-Westphalia, Germany
Johanniter-Krankenhaus Rheinhausen GmbH Hämatologie / Internistische Onkologie / Tagesklinik
Duisburg, North Rhine-Westphalia, Germany
Universitätsklinikum Düsseldorf Klinik für Hämatologie, Onkologie und Klinische Immunologie
Düsseldorf, North Rhine-Westphalia, Germany
Marienhospital
Düsseldorf, North Rhine-Westphalia, Germany
Universitätsklinikum Essen Klinik für Hämatologie
Essen, North Rhine-Westphalia, Germany
Mühlenkreiskliniken Johannes Wesling Klinikum Minden Klinik für Hämatologie, Onkologie und Palliativmedizin
Minden, North Rhine-Westphalia, Germany
Universitätsklinikum Magdeburg
Magdeburg, Sachesen-Anhalt, Germany
Klinikum Chemnitz gGmbH Klinik für Innere Medizin III
Chemnitz, Saxony, Germany
Universitätsklinikum Dresden Medizinische Klinik und Poliklinik I
Dresden, Saxony, Germany
Universitätsklinikum Halle (Saale)
Halle, Saxony-Anhalt, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.